| - | | Pharmaceutical composition for preventing or treating SNCG overexpression disease comprising an AZ-628 as an active ingredient | 양시영 |
| - | | Pharmaceutical composition for preventing or treating SNCG overexpression disease comprising an PD-184352 as an active ingredient | 양시영 |
| - | | Pharmaceutical Composition for Preventing or Treating Synucleinopathy Comprising Expression or Activation Inhibitor of c-src | 박상면, 최유리 |
| - | | Pharmaceutical composition for the prevention or treatment of diseases associated with immune dysregulation comprising oxidized immunoglobulin | 남동호 |
| - | | Pharmaceutical composition for the prevention or treatment of diseases associated with immune dysregulation comprising oxidized immunoglobulin | 남동호 |
| 2017 | | Pharmaceutical composition for treating CNS injury-related diseases comprising CCL2 or CCL2 agonist | 권민정, 김병곤 |
| 2014 | | Pharmaceutical composition for treating or preventing cancer disease comprising proteasome inhibitor and loperamide | 김인영, 최경숙 |
| - | | Pharmaceutical composition for treating temporomandibular joint osteoarthritis comprising Vitamin D | 강정현 |
| - | | Pharmaceutical composition of TIS21/BTG2 induser or activator for treatment or prevention of human diseases related with Diaphanous-related formins | 임인경, 최정아 |
| 2015 | | Pharmaceutical composition with antiviral activity comprising inhibitor of MARCH5 expression and screening method thereof | 박용예, 유영석, 조혜성 |
| 2022 | | Pharmaceutical compositions for angiogenesis inhibition comprising metformin as an active ingredient | 배원정, 이다근 |
| 2007 | | Pharmacodynamic characteristics and cardioprotective effects of new NHE1 inhibitors. | 정이숙 |
| 2019 | | Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers | 이진구 |
| 2021 | | Pharmacogenomics of Hypersensitivity to Non-steroidal Anti-inflammatory Drugs | 박해심 |
| 2015 | | Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study. | 조두연 |
| 1996 | | Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. | 문창현 |
| 1996 | | Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. | 문창현 |
| 2019 | | Pharmacokinetic profile of propyl paraben in humans after oral administration | 이승호 |
| 2017 | | Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults | 김언혜 |
| 1998 | | Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. | 문창현, 백은주, 이수환, 이희주, 정이숙 |
